Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 20210643.
- Also identified by DOI 10.1086/651419 and PMC identifier 3591724.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- HIV Protease Inhibitors
- RNA, Viral
- Viral Load
- Drug Monitoring